GutForge: Using AI to Reshape Your Gut Microbiome From Diagnosis to Intervention

GutForge: Using AI to Reshape Your Gut Microbiome From Diagnosis to Intervention

On May 20, 2029, Israeli microbiome company Biomica officially launched GutForge, an AI gut microbiome therapy platform integrating whole-genome sequencing, AI-driven microbiome analysis, and personalized intervention plan generation, covering the complete diagnostic-to-treatment pipeline.

The human gut harbors over 1,000 microbial species totaling 38 trillion organisms. Growing research shows gut microbiome composition is closely linked to obesity, diabetes, depression, and even autism. However, due to microbiome complexity, precise intervention has remained a medical challenge.

Diagnostic System

GutForge's diagnostic system uses metagenomic sequencing. After a patient's stool sample undergoes whole-genome sequencing, GutForge's AI model generates a detailed microbiome analysis report within 72 hours. The report lists not only species and abundance but also flags microbiome abnormal patterns associated with known disease risks.

The AI model was trained on gut microbiome data from over 1.2 million people across 47 countries, covering different ethnicities, dietary habits, and lifestyles. In internal validation, GutForge achieved 86% accuracy in early inflammatory bowel disease warning and 79% in type 2 diabetes microbiome risk assessment.

Treatment Plans

Based on diagnostic results, GutForge generates personalized intervention plans across three levels: dietary adjustment, probiotic supplementation, and fecal microbiota transplantation. For mild dysbiosis, the platform recommends specific dietary fiber and fermented food combinations. For moderate cases, AI-selected probiotic formulations are recommended. For severe dysbiosis, fecal microbiota transplantation is recommended with AI-matched optimal donors.

Biomica's Chief Scientific Officer Yonatan Levi stated: "GutForge doesn't replace physician judgment — it provides doctors with an unprecedented microbiome analysis tool. Previously, physicians could barely meaningfully interpret a microbiome sequencing report; now, GutForge transforms complex data into actionable treatment recommendations."

Clinical Validation

GutForge showed encouraging results in clinical validation. In a randomized controlled trial of 200 inflammatory bowel disease patients, those using GutForge's personalized intervention achieved 67% symptom remission at 12 weeks versus 41% in the standard care control group.

In a study of 500 metabolic syndrome patients, GutForge's recommended dietary adjustments produced an average 4.2 kg weight loss over 16 weeks and 12% reduction in fasting blood glucose.

Market Outlook

The global gut microbiome testing and intervention market is projected to reach $15 billion by 2030. GutForge's full-service pricing is $1,200 per session, including sequencing, analysis, and three months of personalized intervention. Biomica plans to enter the US and European markets by end of 2029.